Clinical trials: Bipolar Disorder I, open to volunteers
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Bipolar Disorder Type I With Mania or Mania With Mixed Features
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features.
- Trial name
- NCT06951711
- Testing
- KarXT
- Where
- 85 sites in United States, China and 9 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Bipolar I Disorder, Depression, Anxiety
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder
This is a randomized, double-blind, placebo-controlled proof-of-concept clinical trial to assess the efficacy and safety of Magnesium-vitamin B6in combination with treatment as usual for treating symptoms of depression, stress…
- Conditions
- Bipolar I Disorder, Depression, Anxiety, Stress
- Trial name
- NCT05837104
- Testing
- Magnesium vitamin B6
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mclean Hospital
Bipolar I Disorder, Bipolar II Disorder
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- NCT06696755
- Testing
- Icalcaprant
- Where
- 33 sites in United States
- Volunteers
- 195 people
- Sponsor
- AbbVie
Mania, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.
- Trial name
- NCT07140913
- Testing
- Xanomeline/Trospium Chloride
- Where
- 109 sites in United States, Argentina and 11 more
- Volunteers
- 424 people
- Sponsor
- Bristol-Myers Squibb
Multimorbidity, Older Adults (65 Years and Older)
Integrated Care for Older Adults With Major Depression and Physical Multimorbidity - The I-CONNECT
The goal of this clinical trial is to learn if I-CONNECT (Integrated Care for Older Adults with Major Depression and Physical Multimorbidity) can improve the health and well-being of older adults with depression or bipolar…
- Conditions
- Multimorbidity, Older Adults (65 Years and Older), Mood Disorders, Depression - Major Depressive Disorder
- Trial name
- I-CONNECT (NCT07211750)
- Testing
- integrated care intervention tailored to the needs of older adults leaving at home with mood disorders and multimorbidity in Leuven
- Where
- Belgium
- Volunteers
- 82 people
- Sponsor
- KU Leuven
Bipolar Disorder I or II
A Compassionate-focused Intervention for Older People with Bipolar Disorder
The aim of this study is to determine whether it is feasible to deliver a 9-session compassionate-focused therapy for older people with bipolar disorder.
- Trial name
- NCT06882590
- Testing
- Compassionate-focused therapy
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Manchester
Schizophrenia, Schizoaffective Disorder
Cerebellar Modulation of Cognition in Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I, Psychosis
- Trial name
- NCT06107764
- Testing
- intermittant theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Mclean Hospital
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, Bipolar I Disorder
Digital Phenotypes for Predicting Depression_Validation
This 12-month, single-site prospective observational study will prospectively monitor the recurrence of mood episodes while continuously collecting passive digital phenotypes in individuals with and without mood disorders.
- Conditions
- Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Mood Disorders
- Trial name
- NCT07880015
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Bipolar Disorder, Alcohol Use Disorder
N-Acetylcysteine for Bipolar and Alcohol Use Disorders
This study will evaluate N-acetylcysteine (NAC) in adults with bipolar disorder and alcohol use disorder. Participants will be randomly assigned to receive NAC or matched placebo for 28 days.
- Trial name
- NCT07913542
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Medical University of South Carolina
Bipolar I Disorder
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived…
- Trial name
- NCT05977023
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Bipolar I Disorder
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo).
- Trial name
- Illuminate1 (NCT07494305)
- Testing
- LB-102
- Where
- 26 sites in United States
- Volunteers
- 320 people
- Sponsor
- LB Pharmaceuticals Inc.
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-100 in Bipolar Disorder With Depression (BD-D)
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used…
- Trial name
- NCT06656416
- Testing
- ALTO-100
- Where
- 68 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alto Neuroscience
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Bipolar Depression, Bipolar I Disorder
SYNCED - SYNChronized Eating in Bipolar Depression Study
Bipolar disorders (BD) are a group of complex disorders that impact mood, behaviour and cognition and are known to cause significant suffering and impairment.
- Conditions
- Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT06560957
- Testing
- Time restricted eating, Eating ad libitum with nutritional counselling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Ottawa
Bipolar Disorder Type I With Mania
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the…
- Trial name
- NCT06929273
- Testing
- KarXT, Lithium, Valproate
- Where
- 184 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Bipolar Disorder I or II, Healthy (Controls)
Decoding Emotional Dynamics in Bipolar Disorder
The goal of this neuroimaging study is to investigate how emotional states fluctuate in people with bipolar disorder (BD) compared to healthy controls, and to understand the neural mechanisms driving mood instability.
- Trial name
- NCT07221864
- Testing
- Think and Regulate Affective State Task
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Laureate Institute for Brain Research, Inc.